BioStock: PK study in focus during Emplicure’s third quarter

25 November 2022 - 08:46

During Emplicure’s third quarter, the focus has been on the pharmacokinetic study with the company’s main project Empli03, which is aimed at patients with chronic pain. A new CEO was also appointed during the quarter and a holding company structure was implemented. BioStock talked to the company’s newly appointed CEO Håkan Engqvist about the past quarter.

Read the full article about Emplicure at

This is a press release from BioStock – Connecting Innovation & Capital.

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
Emplicure AB
Emplicure is a pharmaceutical company that develops new innovative drugs based on the combination of already approved active substances and advanced materials science in bioceramics. The product portfolio initially focuses on drugs for chronic pain and with addictive properties....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More